Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07776054 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT07776054 · ClinicalTrials.gov record · last posted 2026-08-20

Clinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent AF With HFpEF

Name: Clinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent AF With HFpEF — clinical trial record (NCT07776054)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 4

SponsorSamsung Medical Center

Started2024-02-01

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

SGLT2 inhibitors improve outcomes in heart failure across the ejection fraction spectrum, but their effect on maintenance of sinus rhythm after rhythm-control therapy is largely unknown. This prospective, single-center, open-label randomized controlled trial evaluates whether an SGLT2 inhibitor started after successful electrical cardioversion reduces recurrence of atrial tachyarrhythmia at 1 month in patients with persistent atrial fibrillation and heart failure with preserved ejection fraction. 200 patients will be randomized 1:1 to receive an SGLT2 inhibitor or no SGLT2 inhibitor.

Trial Details

NCT Number	NCT07776054
Lead Sponsor	Samsung Medical Center
Conditions	Atrial Fibrillation, SGLT2 Inhibitor, DC Cardioversion
Enrollment	200 participants
Start Date	2024-02-01
Primary Completion	2027-08-01 (estimated)
Study Completion	2027-09-01 (estimated)
Updated on ClinicalTrials.gov	2026-08-20